LEO Pharma
Deep Dive/ R&D/ Views & Analysis/ Views and analysis
LEO Pharma’s new R&D lead on driving agility in drug development
mike.hammerton@pharmaphorum.com
Deep Dive, Jörg Möller, LEO Pharma, patient-centric, R&D, Research and Development 2021
0 Comment
Deep Dive/ R&D/ Views & Analysis/ Views and analysis
Deep Dive: Research and Development
mike.hammerton@pharmaphorum.com
AI, clinical trials, digital health, LEO Pharma, NIHR, rare disease
0 Comment
Podcast/ Sales and Marketing/ Video/ Views & Analysis/ Views and analysis
Gitte Aabo on telemedicine and GN Hearing: the pharmaphorum podcast
Dominic Tyer
COVID-19, Gitte Aabo, GN Hearing, LEO Pharma, podcast, telemedicine
0 Comment
News/ News/ Sales and Marketing
LEO eyeing 2021 US launch for eczema drug tralokinumab
Richard Staines
atopic dermatitis, dermatology, Dupixent, LEO Pharma, Sanofi, tralokinumab
0 Comment
Eyeing Dupixent’s territory, Leo Pharma files tralokinumab in EU
Phil Taylor
atopic dermatitis, dermatology, Dermira, Dupixent, Eli Lilly, LEO Pharma, Pfizer, Sanofi, tralokinumab
0 Comment
Patients/ Views & Analysis/ Views and analysis
Towards Patient Centricity: LEO Pharma
Amanda Barrell
LEO Pharma, patient centricity, psoriasis, Towards Patient Centricity
0 Comment
Digital/ News/ News/ News/ Oncology
Smartphone app provides skin cancer early warning service
Richard Staines
digital health, LEO Pharma, skin cancer, SkinVision
0 Comment
Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
Almirall gets in on the eczema action
Richard Staines
Almirall, atomic dermatitis, Dupixent, eczema, LEO Pharma, Sanofi
0 Comment